Filing Flows › Co-Diagnostics (CODX) › Q1 2026 › vs Q1 2025
Co-Diagnostics (CODX) Q1 2026 vs Q1 2025 (year over year)
Co-Diagnostics's revenue rose $96K (+190%) from $50K in Q1 2025 to $146K in Q1 2026.
Co-Diagnostics, Q1 2026: revenue $146K (+190% year over year), net loss $9.1M, operating cash flow −$7.8M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $146K | $50K | $96K | +190% |
| Other income, net | $69K | $1.0M | −$962K | -93% |
| Net loss | $9.1M | $7.5M | $1.6M | +21% |
| Costs & expenses | $9.4M | $8.6M | $741K | +9% |
| Operating costs | $9.4M | $8.6M | $752K | +9% |
| Income tax | $1K | $12K | −$11K | -96% |
| Research & development | $5.9M | $4.9M | $1.1M | +22% |
| Sales & marketing | $468K | $657K | −$189K | -29% |
| General & admin | $2.5M | $2.8M | −$270K | -10% |
| Other operating costs | $255K | $280K | −$25K | -9% |
| Operating cash sources | $9.1M | $7.5M | $1.6M | +21% |
| Depreciation & amortization | $255K | $280K | −$25K | -9% |
| Share-based compensation | $219K | $875K | −$656K | -75% |
| Working capital & other | $819K | −$2.4M | $3.2M | — |
| Cash used in operations | $7.8M | $8.7M | −$899K | -10% |
| Net loss absorbed | $9.1M | $7.5M | $1.6M | +21% |
Questions
How much did Co-Diagnostics's revenue grow year over year in Q1 2026?
Co-Diagnostics's revenue rose $96K (+190%) from $50K in Q1 2025 to $146K in Q1 2026.